Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial will
compare the relative efficacy and safety of intravitreal methotrexate, intravitreal
ranibizumab, and the intravitreal dexamethasone implant for the treatment of uveitic macular
edema persisting or reoccurring after an intravitreal corticosteroid injection. MERIT is a
parallel design (1:1:1), randomized comparative trial with an anniversary close-out at the 6
month clinic visit. The primary outcome is percent change in central subfield thickness from
the baseline OCT measurement to the 12 week visit.